Education
About Us
Working with TipRanks
Follow Us
60 Degrees Pharmaceuticals, Inc. (SXTP)
:SXTP
RESEARCH TOOLSreports
SXTP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.41 - $36.07
Previous CloseN/A
Volume13.44M
Average Volume (3M)47.35K
Market Cap
$2.61M
Enterprise Value$7.69M
Total Cash (Recent Filing)$115.40K
Total Debt (Recent Filing)$18.80M
Price to Earnings (P/E)―
Beta1.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.07
Shares Outstanding1,472,891
10 Day Avg. Volume24,477
30 Day Avg. Volume47,351
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.92
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap2.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit34.51
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$3.40Price Target Upside92.09% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical SuccessA published clinical case series showed Arakoda displayed an 80% cure rate in patients with persistent, relapsing babesiosis who had failed previous treatments.
FDA DesignationArakoda was granted FDA Orphan Drug Designation for the treatment of babesiosis, enhancing its potential market value for a rare disease.
Sales GrowthArakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.
Bears Say
Evaluation DifficultyThe analyst maintains a Neutral rating due to difficulties in evaluating the company prior to receiving clinical data from the babesiosis program.
Market InsightThere is little insight into the malaria market currently, with the analyst awaiting findings from the company's pilot program for more information.
---
Options Prices
Currently, No data available
---
Ownership Overview
24.84% Insiders
0.45% Mutual Funds
1.36% Other Institutional Investors
74.71% Public Companies and
Individual Investors
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.41 and its highest was $36.07 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $2.61M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
60 Degrees Pharmaceuticals, Inc. released its earnings results on Aug 14, 2024. The company reported -$21.175 earnings per share for the quarter, the consensus estimate of -$21.175 by $0.
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 1,472,891 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
60 Degrees Pharmaceuticals, Inc. reported an EPS of -$21.175 in its last earnings report, expectations of -$21.175. Following the earnings report the stock price went down -3.061%.
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
---
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
---
SXTP Stock 12 Month Forecast
Average Price Target
$3.40
▲(92.09% Upside)
Technical Analysis
Best Analysts Covering SXTP
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-80.60%
reiterated a buy rating 5 months ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -80.60% per trade.
---